Abbott starts major ZoMaxx DES trial
This article was originally published in Clinica
Executive Summary
Abbott Laboratories' vascular devices division says it has reached a key milestone in its bid to enter the coronary drug-eluting stent (DES) sector, by enrolling the first patient in a 400 patient, prospective, randomised clinical trial of its DES, ZoMaxx.